Listed by the USPTO as REILLY, SOPHIA JANE
Tech Center 1600 • Art Units: 1627 1629
This examiner grants 60% of resolved cases
REILLY, SOPHIA JANE handles cases in tech center 1600 and art unit 1627. The profile shows 80 resolved cases, a 60.0% allowance rate, and a median of 1210 days to allowance. The interview lift is 49.4%, indicating a strong association between interviews and improved allowance outcomes in the available data.
The leading companies are Hoffmann-La Roche Inc., The Ohio State University, and THE GENERAL HOSPITAL Corporation. The listed firms are Meunier Carlin & Curfman LLC, SCULLY SCOTT MURPHY & PRESSER, PC, and COOLEY LLP. The limited case volume calls for application-specific review, but the interview signal supports early preparation for examiner discussions. The 1210-day median also indicates that counsel should plan for extended prosecution and coordinate continuation decisions with research, development, and commercialization timelines.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18844654 | COMBINATION THERAPIES FOR BREAST CANCER | Non-Final OA | Hoffmann-La Roche Inc. |
| 18068407 | AMIDOPYRIMIDONE DERIVATIVES | Non-Final OA | Hoffmann-La Roche Inc. |
| 18867144 | PEPTIDYL FLAVOR MODIFIERS | Non-Final OA | Ohio State Innovation Foundation |
| 18033178 | METHODS TO SENSITIZE TUMORS TO TREATMENT BY IMMUNOTHERAPY | Non-Final OA | Ohio State Innovation Foundation |
| 18730214 | IMMUNOMODULATORY LIPIDS AND USES THEREOF | Non-Final OA | The General Hospital Corporation |
| 18563575 | MMP13 AS A THERAPEUTIC TARGET FOR ALLERGIC INFLAMMATORY DISEASES | Final Rejection | The General Hospital Corporation |
| 17928496 | COMPOSITIONS AND METHODS FOR TREATING VIRUS INFECTION | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18844645 | CALCIMYCIN AS ANTIFUNGALS | Non-Final OA | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA |
| 18852426 | N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES | Non-Final OA | Takeda Pharmaceutical Company Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy60.0% of resolved applications examined by Sophia Jane Reilly were allowed (80 resolved cases), compared with 35.1% across Art Unit 1627 over the last five years.
This examiner's interview lift is +49.4 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Sophia Jane Reilly took 1,210 days on average from filing to allowance.
Sophia Jane Reilly examines applications in Art Unit 1627 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
